Bristol-Myers Squibb Community
NYSE:BMY Community- 2 Narratives written by author
- 0 Comments on narratives written by author
- 233 Fair Values set on narratives written by author
Community Investing Ideas
EV
Community Contributor
Bristol Myers Squibb (BMY): Undervalued Opportunity or Value Trap? A Deep Dive into 2024 Earnings and Fair Value
Fourth Quarter 2024 Highlights: Total Revenues: $12.3 billion, an 8% increase from the same period in 2023. GAAP Earnings Per Share (EPS): $0.04, a significant decrease from $0.87 in Q4 2023.
View narrativeUS$65.00
FV
6.2% undervalued intrinsic discount2.43%
Revenue growth p.a.
2users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
about 1 month ago author updated this narrative
AN
Consensus Narrative from 21 Analysts
Relaunch Into Neuroscience With Cobenfy Will Diversify Future Drug Portfolio
Key Takeaways Relaunch into neuroscience with Cobenfy shows potential for revenue through expansion into Alzheimer's and bipolar disorder. Operational and financial strategies focus on cost savings and accelerated R&D to strengthen margins and boost profitability.
View narrativeUS$61.24
FV
0.4% undervalued intrinsic discount-3.89%
Revenue growth p.a.
1users have liked this narrative
0users have commented on this narrative
168users have followed this narrative
6 days ago author updated this narrative